http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
비특이 면역증강제 BARODON<sup>ⓡ</sup>의 항원성시험
조은혜,조성대,안남식,정지원,양세란,박준석,박기수,홍인선,서민수,이영순,강경선,Jo, Eun-hye,Cho, Sung-dae,Ahn, Nam-shik,Jung, Ji-won,Yang, Se-ran,Park, Joon-suk,Park, Ki-su,Hong, In-sun,Seo, Min-su,Tiep, Nguyeu Ba,Lee, Yong-soon,Kang, K 대한수의학회 2003 大韓獸醫學會誌 Vol.43 No.2
The antigenicity of nonspecific immunostimulator BARODON$^{(R)}$, a newly developed drug, was investigated by tests for passive cutaneous anaphylaxis (PCA) and active systemic anaphylaxis (ASA) in mice and guinea pigs. In ASA test using guinea pigs, there were no significant clinical symptoms in all individuals of low(0.3%) and high(3%) dose of both groups treated with only BARODON$^{(R)}$ and cotreated with BARODON$^{(R)}$ and adjuvant group. In PCA test, blue spots of Evan's were observed from $2^6$ to $2^{10}$ in homologous group and from $2^2{\sim}2^5$ dilution rate in heterologous group of BSA treated positive control group. However, intradermal sensitization with antiserum obtained from low (0.3%) and high (3%) dose of BARODON$^{(R)}$ only treatment group and treated-with-adjuvant group, followed by intravenous injection of respective antigen and Evan's blue mixture (1:1) showed no blue spot observed. In conclusion, BARODON$^{(R)}$, as showed in ASA and PCA test, did not cause anaphylatic shock when treated 3 and 10 times higher than clinically intended dose, nor induce IgE, so that might not have antigenic properties in mice and guinea pigs.
랫드와 비글에서 GC-100X 세정제의 독성에 대한 연구
강경선,조성대,안남식,정지원,양세란,박준석,박기수,홍인선,서민수,조은혜,이영순,Kang, Kyung-Sun,Cho, Sung-Dae,Ahn, Nam-Shik,Jung, Ji-Won,Yang, Se-Ran,Park, Joon-Suk,Park, Ki-Soo,Hong, In-Sun,Seo, Min-Soo,Jo, Eun-Hye,Nguyen, Ba Tiep,Lee, 대한수의학회 2004 大韓獸醫學會誌 Vol.44 No.1
Because cleaning products are part of our everyday lives, it is essential that they should not present significant risks to health. However, many petrochemicals in most soaps and detergents can be absorbed through the scalp and skin and, over time, accumulate in the organs and tissues. This accumulation may result in brain, nerve, and liver damage. Therefore, it is interested in developing non-harmful detergent. According to Korea Research Institute of Chemical Technology, GC-100X may be non-harmful and non-corrosive alkaline ionic water (pH 12). It is composed of hydroxyl radicals and supplemented with xylitol. To evaluate influence of GC-100X on rats and beagles, GC-100X was diluted with distilled water (25%, 50%, and 100% solution respectively). Each of diluted GC-100X was daily treated per oral. In body weight analysis, urinary analysis, ophthalmological test and autopsy, we did not find any significance, but in serum biochemical analysis and hematological analysis, we found some significances in middle dose group compared with control group. These significances in serum biochemical analysis and hematological analysis may be not induced by GC-100X, because it was not found to be significant from control group in histopathological examination. Thus, it is concluded that NOEL(No Observed Effect Level) of GC-100X may be higher than all treatment doses used in this study, and GC-100X may be a non-toxic detergent.
서민수(Min-Su Seo),조성대(Sung-Dae Cho),안남식(Nam-Shik Ahn),정지원(Ji-Won Jung),양세란(Se-Ran Yang),박준석(Joon-Suk Park),박기수(Ki-Su Park),홍인선(In-Sun Hong),조은혜(Eun-Hye Jo),Nguyen Ba Tiep(Nguyen Ba Tiep),이영순(Yong-Soon L 한국독성학회 2003 Toxicological Research Vol.19 No.2
A nonspecific immunostimulator BARODON® was tested for mutagenicity using Ames Salmonella tester strains TA98, TA100, TA102, TA1535 and TA1537 with or without metabolic activation<br/> (S9 mix). None of the fresh species showed mutagenicity. In the reverse mutation test using Salmonella typhimurium TA98, TA100, TA102, TA1535 and TA1537 did not increase the number of revertants at all doses tested (5, 2.5 or 1.25 mg/ml). Chromosome aberration test was carried out in Chinese hamster lung (CHL) cell line. The cells were treated with BARODON® (1, 0.5 or 0.25 mg/ml), while positive control group was treated with Mitomycin C (0.1 mg/ml). The results show that there is no statistically significant difference between positive control and treatment groups. In mouse micronucleus test, there was significant increase in the ratio of micronucleated polychromatic erythrocyte (MNPCE) in the high dose group (10% BARODON®), while there is no significance between control and low (2.5% BARODON®) or middle (5% BARODON®) dose groups. Taken togather, this results suggest that below 5% BARODON® might not have mutagenic potential in vitro and vivo systems.
급성 심근 경색 환자에서 재관류 방법에 따른 P파폭과 P파 분산의 변화
최웅길 ( Woong Gil Choi ),김대혁 ( Dae Hyeok Kim ),김기창 ( Gi Chang Kim ),안인선 ( In Sun Ahn ),김수현 ( Soo Hyun Kim ),유형권 ( Hyung Kwon Yu ),권준 ( Jun Kwan ),박금수 ( Keum Soo Park ),이우형 ( Woo Hyung Lee ) 대한내과학회 2007 대한내과학회지 Vol.73 No.5
Background: P wave dispersion (PWD) and P wave duration have been used to evaluate the discontinuous propagation of sinus impulse and the prolongation of atrial conduction time, respectively. This study was conducted to compare the change of the maximal P wave duration (Pmax) and PWD according to the treatment strategy used in patients with an acute myocardial infarction (AMI). Methods: We retrospectively evaluated 86 patients that experienced an AMI. Patients were classified into three groups according to the treatment strategy: primary percutaneous coronary intervention (PCI), thrombolytic therapy, and delayed PCI. ECGs that were obtained from all patients on admission and on the second day were analyzed. The Pmax and minimum P wave duration (Pmin) were measured from a 12-lead ECG. The PWD was calculated as the difference between the Pmax and Pmin. Result: There was no significant difference in the age, gender, medication, coronary risk factor, ejection fraction, left atrial diameter, basal Pmax and PWD among the groups. However, there were significant differences in P max and PWD between the primary PCI group and the other groups on the second day after hospital admission. In the thrombolytic therapy and delayed PCI groups, the PWD was significantly lower in the patients with a patent infarct-related artery (IRA) than in patients without a patent IRA on the second day after hospital admission. Conclusions: These findings suggest that a primary PCI decreased the Pmax and PWD more than thrombolytic therapy or a delayed PCI.(Korean J Med 73:489-495, 2007)